COVID-19, diabetes mellitus and co-morbidities: a cardiologist’s view


Authors: Andrej Dukát 1;  Juraj Payer 1;  Fedor Šimko 2
Authors‘ workplace: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava 1;  Ústav patologickej fyziológie LF UK, Bratislava 2
Published in: Forum Diab 2022; 11(1): 7-9
Category:

Overview

Ongoing pandemy caused by novel coronavirus affected almost 200 countries all over the world. Most of the available studies have shown that with COVID -19 (COronaVIrus Disease 2019) diabetes mellitus as a distinctive comorbidity is associated with more severe disease, acute respiratory distress syndrome and increased mortality in this group of infected patients. At present we are facing new challenges regarding the changed health situation.

Keywords:

cardiovascular diseases – diabetes mellitus – COVID -19


Sources

1. Yang J, Zheng Y, Gou X et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91–95. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijid.2020.03.017>.
2. Emami A, Javanmardi F, Pirbonyeh N et al. Prevalence of underying diseases in hospitalized patients with Covid-19: a systematic review and meta-analysis. Arch Acad Emerg Med 2020; 8(1): e35.
3. Li B, Yang J, Zhao F et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020;109(5): 531–538. Dostupné z DOI: <http://dx.doi.org/10.1007/s00392–020–01626–9>.
4. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-18 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054–1062. Dostupné z DOI:<http://dx.doi.org/10.1016/S0140–6736(20)30566–3>.
5. Wan S, Xiang Y, Fang W et al. Clinical features and treatment of Covid-19 patients in northeast Chongqing. J Med Virol 2020; 201(11): 1372–1379. Dostupné z DOI: <http://dx.doi.org/10.1164/rccm.202003–0543OC>.
6. Guan WJ, Liang WH, Thao Y et al. [China Medical Treatment Expert Group for Covid-19]. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J 2020: 55(5): 2000547. Dostupné z DOI: <http://dx.doi.org/10.1183/13993003.00547–2020>.
7. Papazafiropoulou AK, Antonopoulos S. The COVID-19 pandemic and diabetes mellitus. Arch Med Sci Atheroscler Dis 2020; 5: e200-e205. Dostupné z DOI: <http://dx.doi.org/10.5114/amsad.2020.97435>.
8. Yang X, Yu Y, Xu J et al. Clinical course and outcomes in critically ill patients with SARS-COV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8(5): 475–481. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–2600(20)30079–5>.
9. Guan W, Ni Z, Hu Y et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708–1720. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2002032>.
10. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected by SARS-CoV-1 in Wuhan, China. Allergy 2020; 75(7): 1730–1741. Dostupné z DOI: <http://dx.doi.org/10.1111/all.14238>.
11. Deng SQ, Peng HJ. Characteristics of and public health responses to the Coronavirus disease 2019 outbreak in China. J Clin Med 2020:9(2); 575. Dostupné z DOI: <http://dx.doi.org/10.3390/jcm9020575>.
12. Wu C, Chen X, Cai Y et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180(7): 934–943. Dostupné z DOI: <http://dx.doi.org/10.1001/jamainternmed.2020.0994>.
13. Leung C. Clinical features of deaths in the novel coronavirus epidemic in China. Rev Med Virol 2020; 30(3): e2103. Dostupné z DOI: <http://dx.doi.org/10.1002/rmv.2103>.
14. Istituto Superiore di Sanita. Report of characteristics of patients died positive for COVID-19 in Italy. Dostupné z WWW: <https://www.epicentro.iss.it/>. [19–03–2020].
15. Bhatraju PK, Ghassemieh BJ, Nichols M et al. Covid-19 in critically ill patients in the Seattle region – case series. N Engl J Med 2020: 323:2052–2059.
16. Richardson S, Hirsc JS, Narasimhan M et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020; 3238(20): 2051–2059. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2020.6775>.
17. Garg S, Kim I, Whitaker M et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 – COVID-NET- 14 States, March 1–30, 2020. Morb Mortal Wkly Rep 2020; 69(15): 458–464. Dostupné z DOI: <http://dx.doi.org/10.15585/mmwr.mm6915e3>.
18. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (Covid-19) outbreak in China: summary of report of 72314 cases from the chinese center for disease control and prevention. JAMA 2020; 323: 1239–1242. Dostupné z DOI:<http://dx.doi.org/10.1001/jama.2020.2648>.
19. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to Covid-19 in Italy. JAMA 2020; 323(18): 1775–1776. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2020.4683>.
20. Roncon L, Zulin M, Rigatelli G et al. Diabetic patients with Covid-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol 2020; 127: 104354. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcv.2020.104354>.
21. Zhou J, Tan J. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China. Metabolism 2020; 107: 154216. Dostupné z DOI: <http://dx.doi.org/10.1016/j.metabol.2020.154216>.
22. Raj VS, Mou H, Smits SI et al. Dipeptidylpeptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495(7440): 251–254. Dostupné z DOI: <http://dx.doi.org/10.1038/nature12005>.
23. Rizzo M, Nikolic D, Banach M et al. Incretin-based therapies, glucometabolic health and endovascular inflammation. Curr Pharm Des 2014; 20(31): 4953–4960. Dostupné z DOI: <http://dx.doi.org/10.2174/1381612819666131206102255>.
24. Amin EF, Rifaal RA, Abdel-Latif RG. Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory apo-ptotic pathway. Fundam Clin Pharmacol 2020; 34(5): 548–558. Dostupné z DOI: <http://dx.doi.org/10.1111/fcp12548>.
25. Dapagliflozin in respiratory failure in patients with COVID-19 (DARE-19). Clinical-Trials gov website. Dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT04350593>.
26. Kosiborod M, Berwanger O, Koch GG et al. Effect of dapagliflozin on major clinical events and recovery in patients with respiratory failure because of COVID-19. Diabetes Obes Metab 2021; 23(4): 886–896. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.14296>.
27. American Diabetes Association. COVID-19. Dostupné z WWW:<https://www.diabetes.org/coronavirus-covid-19>.
28. Williams DM, Nawaz A, Evans M. Diabetes and Novel Coronavirus Infection: Implications for Treatment. Diabetes Ther 2020; 11(9): 1915–1924. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–020–00858–2>.

Labels
Diabetology Endocrinology Internal medicine
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account